Translate this page into:
Value of Indium-111 Octreotide Scintigraphy in Neuroendocrine Tumors
Correspondence to: Anjali Jain Department of Nuclear Medicine. Sir Ganga Ram Hospital, New Delhi-110060 Ph No. +91-11-25 9350544552, Fax No: 25861671, 25861696 E-mail: dr.anjalimittal@yahoo.co.in
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Somatostatin receptors are over expressed in several neuroendocrine tumors making these receptors potential targets for radionuclide diagnosis and therapy. Indium-111 - DTPA octreotide is a somatostatin analog that has been used for detecting somatostatin receptor positive tumors for years. Somatostatin receptor scintigraphy and octreotide therapy have changed the management of neuroendocrine tumors. The object of this report is to highlight the role of radionuclide scintigraphy and therapy in neuroendocrine tumors.
